Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424605 | 1.00 | GABRR1 (0.56) | GABRR1SLC7A5GSRGABRPGABRD | |
| SCHEMBL2324416 | 1.00 | GABRR1 (0.56) | GABRR1SLC7A5GSRGABRPGABRD | |
| SCHEMBL2334387 | 1.00 | GABRR1 (0.56) | GABRR1SLC7A5GSRGABRPGABRD | |
| SCHEMBL8018052 | 1.00 | GABRR1 (0.56) | GABRR1SLC7A5GSRGABRPGABRD | |
| SCHEMBL2330401 | 1.00 | GABRR1 (0.56) | GABRR1SLC7A5GSRGABRPGABRD | |
| Hydrochloric Acid SCHEMBL9114616 | 0.98 | GABRR1 (0.54) | GABRR1SLC7A5GSRGABRPGABRD | |
| Hydrochloric Acid SCHEMBL8667200 | 0.98 | GABRR1 (0.54) | GABRR1SLC7A5GSRGABRPGABRD | |
| SCHEMBL8015462 | 0.86 | GSR (0.48) | GABRR1SLC7A5GSRGABRPGABRD | |
| SCHEMBL2420751 | 0.86 | GSR (0.48) | GABRR1SLC7A5GSRGABRPGABRD | |
| SCHEMBL2420748 | 0.86 | GSR (0.48) | GABRR1SLC7A5GSRGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226496-A1 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2022-07-21 | — | — | US | claimed |
| EP-3964236-A1 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | LegoChem Biosciences, Inc. (KR) | 2022-03-09 | — | — | EP | claimed |
| CN-113727734-A | Ligand-drug conjugates comprising a linker having a tris structure | 乐高化学生物科学股份有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-09 | — | — | US | claimed |
| EP-3380125-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LegoChem Biosciences, Inc. (KR) | 2018-10-03 | — | — | EP | claimed |
| CN-108136038-A | Conjugates comprising peptide groups and methods related thereto | 乐高化学生物科学股份有限公司 | 2018-06-08 | — | — | CN | claimed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | claimed |
| US-20260124278-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS | D&D PHARMATECH INC (KR) | 2026-05-07 | — | — | US | disclosed |
| EP-4689125-A1 | UNNATURAL AMINO ACID IN CELLULO SYNTHESIS FOR SITE-SPECIFIC PROTEIN MODIFICATION | The Chinese University of Hong Kong (HK) | 2026-02-11 | — | — | EP | disclosed |
| US-20250296960-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | D&D PHARMATECH INC. (KR) | 2025-09-25 | — | — | US | disclosed |
| US-20250127723-A1 | PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT | D&D PHARMATECH INC. (KR) | 2025-04-24 | — | — | US | disclosed |
| EP-4531925-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS | D&D Pharmatech Inc. (KR) | 2025-04-09 | — | — | EP | disclosed |
| EP-4532530-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE THREOF | D&D Pharmatech Inc. (KR) | 2025-04-09 | — | — | EP | disclosed |
| CN-108136038-A | Conjugates comprising peptide groups and methods related thereto | 乐高化学生物科学股份有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-107847605-A | Antibody-drug conjugates comprising branched linkers and methods related thereto | 乐高化学生物科学股份有限公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2017089895-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| US-8765910-B2 | Method for amidating polypeptides with basic amino acid C-terminals by means of specific endoproteases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20100311112-A1 | METHOD FOR AMIDATING POLYPEPTIDES WITH BASIC AMINO ACID C-TERMINALS BY MEANS OF SPECIFIC ENDOPROTEASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| CN-101268097-A | Method for amidating polypeptides with a basic amino acid C-terminus by means of specific endoproteases | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | DAO, LPO, TYRO3 | GABRR1 928/4885SLC7A5 217/4885GSR 2760/4885 |
| US-20250127723-A1 | PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT | CYP7A1, CYP11B1, CYP11B2 | GABRR1 1005/4885SLC7A5 362/4885GSR 228/4885 |
| US-20220226496-A1 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | TNFSF10, TNFRSF9, ANTXR2 | GABRR1 1190/4885SLC7A5 1458/4885GSR 4145/4885 |
| US-20250296960-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | GLP1R, IAPP, GIPR | GABRR1 78/4885SLC7A5 662/4885GSR 744/4885 |
| US-20260124278-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS | GLP1R, IAPP, VIP | GABRR1 225/4885SLC7A5 291/4885GSR 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.